01.04.24 -- Moving Beyond AAV: The Next Generation Of Vectors In CGT

Meet the demand for AAV-based gene therapies by using design-of-experiment and fit-for-purpose plasmids and transfection reagents.

With industry-leading scientific expertise and customer support, we have pioneered solutions to some of the most pressing challenges facing customers interested in adopting MAM into their organizations.

Cell separation techniques enable protein purification and the removal of contaminants. Explore how the processing speed of cell separation can impact quality, process efficiency, and overall economics.

It's essential to understand how scaling up is affecting your aseptic filling operations. Here are four topics to consider to help ensure your drug product will be taken care of and ready for production.

Diseases that lack a cure, or even treatment, may be addressed with new gene therapeutic classes. This potential has spurred new investments in the drug development and commercialization space.

Are you seeking guidance to evaluate cleanroom design/built parameters? Utilize this guide to better understand the total cost of ownership and how to perform a fast and effective cost-benefit analysis.

Compare expansion parameters when adherent cells are cultured on the small and standard bioreactors using a hollow-fiber bioreactor platform.

Access this report where the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol was used to achieve gene editing in primary T cells with high efficiency while maintaining high cell viability.

AGC Biologics discusses its journey to the successful implementation of iCELLis bioreactors in their AAV and lentivirus platforms.

As CRISPR use continues to grow, so has the demand for clinical-grade guide RNA. Learn about GMP sgRNA and their stringent process and manufacturing controls.